Here are relevant reports on : gastrointestinal-cancer-therapeutics-market
-
Gastrointestinal Products Market | Gastroenterology Products Market by Devices (Endoscopy, Ablation system, Motility testing, Biopsy devices, Stenting devices, pH monitoring), Diseases (GERD), (IBD), Gastrointestinal cancer), End-User (Hospitals, ASC) - Global Forecast to 2029
The global gastrointestinal products market, valued at US$13.8 million in 2023, stood at US$14.7 million in 2024 and is projected to advance at a resilient CAGR of 6.1% from 2024 to 2029, culminating in a forecasted valuation of US$19.7 million by the end of the period. Market growth can be attributed to the growing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), and colorectal cancer, which drives the demand for diagnostic and therapeutic products.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Fiber Food Ingredients Market By Type Soluble Fiber, Insoluble Fiber, Resistant Fibres, Others) By Function (Cancer Diabetes, Gastrointestinal Health, Prebiotics, Heart Disease, Weight Management) By Geography
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023
The global oncology nutrition market is expected to reach USD 2.21 Billion by 2023 from USD 1.46 Billion in 2018, at a CAGR of 8.7%. Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth. The prominent players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany).
- Published: April 2018
- Price: $ 16000
- TOC Available:
-
Synthetic Stem Cells Market by Application (Cardiovascular Disease, Neurological Disorders, Other Applications (Cancer, Diabetes, Gastrointestinal, Musculoskeletal Disorders)), Region (North America (US, Canada), Europe, APAC, RoW) - Global Forecast to 2028
The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market. The key developers of synthetic stem cell technology are North Carolina State University (NCSU) (US) and Zhengzhou University (China).
- Published: December 2018
- Price: $ 4950
- TOC Available:
-
Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023
Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
